Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

Inclusion Criteria

• •Patients:
• •Age\>18 years
• •Informed consent signed by the patient
• •Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis
• •Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \[1\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).
• •Healthy controls :
• •Age\>18 years
• •Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
• •Informed consent signed by the patient
• •Absence of known cutaneous or systemic inflammatory disease.